One To Watch
Scribe Therapeutics
Company Overview
A UC Berkeley spinout deploying engineered CRISPR-CasX technology against lipid-driven cardiovascular disease, with its PCSK9-silencing lead STX-1150 projected to enter the clinic in mid-2026 and more than $25 million in fresh CIRM funding behind two preclinical programs. Scribe Therapeutics is an Alameda, California-based clinical-stage biotechnology company building a pipeline of potentially one-time genetic medicines targeting the key lipid drivers of atherosclerotic cardiovascular disease. The company's thesis is that its proprietary X-Editing enzyme platform can do what conventional CRISPR cannot: deliver durable gene silencing in vivo with the efficacy, specificity, and compact size needed to reach the liver safely and at scale. With over $2.7 billion in partnership deal value signed to date and a founding team rooted in the original CRISPR patent estate, Scribe sits at an interesting intersection of deep science and serious commercial momentum.
Headquarters and Global Presence
Scribe is headquartered in Alameda, California, and emerged from Jennifer Doudna's laboratory at the University of California, Berkeley. Its operations reflect a California-centric model backed by state research funding through CIRM alongside its private partnerships.
Founding and History
Scribe was co-founded by Jennifer A. Doudna, PhD, Benjamin L. Oakes, PhD, David F. Savage, PhD, and Brett Staahl, PhD — a founding quartet drawn directly from the Berkeley lab where CRISPR-Cas9 was first characterized. The company spun out around the CRISPR-CasX molecule, a naturally occurring CRISPR enzyme distinct from Cas9. In March 2021, Scribe raised $100 million in a Series B financing round to advance its X-Editing platform and early pipeline. Since then, strategic partnerships with Eli Lilly's Prevail Therapeutics and Sanofi have added substantial non-dilutive capital and extended the platform's reach beyond cardiometabolic disease.
Therapy Areas and Focus
Scribe's proprietary pipeline is focused on cardiometabolic disease — specifically the genetically validated lipid targets that drive atherosclerotic cardiovascular disease, severe hypertriglyceridemia, and familial chylomicronemia syndrome. PCSK9, LPA, and APOC3 are each supported by decades of human genetic evidence linking loss-of-function variants to dramatically reduced cardiovascular risk, making them among the most de-risked targets in the entire cardiovascular field. The strategic logic is that a single durable gene-editing intervention could replace a lifetime of daily or monthly lipid-lowering therapy. Beyond its owned pipeline, Scribe's platform has also been licensed into neurological and neuromuscular disease through its Prevail collaboration.
Technology Platforms and Modalities
Scribe's X-Editing platform centers on CRISPR-CasX, an engineered enzyme that is smaller than the widely used Cas9 and, critically, not derived from pathogen molecules — a distinction that may reduce pre-existing immune responses in patients. The company engineers these XE molecules through a directed design process, optimizing for efficacy, on-target specificity, and in vivo deliverability rather than relying on naturally occurring sequences. The smaller size of CasX relative to Cas9 is practically significant: it enables more efficient packaging into adeno-associated viral or lipid nanoparticle delivery vehicles, the two dominant vectors for liver-targeted gene medicine. Scribe frames its approach as CRISPR by Design — a manufacturing and optimization philosophy aimed at producing clinical-grade, programmable enzymes at scale.
Key Pipeline and Programs
STX-1150 is Scribe's lead asset and the program closest to generating clinical data. It is a CRISPR epigenetic silencing therapy targeting the PCSK9 gene, designed to produce durable reduction of LDL cholesterol through a single administration. The program was projected to enter Phase I clinical trials in mid-2026, which would make it among the first in vivo CRISPR cardiometabolic programs to reach human testing.
STX-1200 targets the LPA gene to reduce lipoprotein(a), an independent and genetically elevated cardiovascular risk factor for which no approved therapy yet achieves durable lowering. Elevated Lp(a) affects roughly one in five people globally and is not meaningfully addressed by statins — the commercial white space is real. STX-1200 is currently preclinical and is one of the two programs supported by the CIRM award announced on June 19, 2026.
STX-1400 targets the APOC3 gene, with the objective of lowering triglyceride-rich lipoproteins for patients with severe hypertriglyceridemia and familial chylomicronemia syndrome — rare but life-threatening conditions with limited treatment options. Like STX-1200, it is preclinical and CIRM-funded, with the award designed to accelerate both programs toward IND-enabling studies.
Recent Developments
On June 19, 2026, Scribe announced it had been awarded more than $25 million from CIRM to advance STX-1200 (LPA/Lp(a)) and STX-1400 (APOC3/triglycerides) toward the clinic — the company's most recent significant financing event and a validation of its cardiometabolic-first strategy by California's state regenerative medicine body. The CIRM awards are positioned as supporting first-in-class genetic medicines with a single-dose, durable lowering profile. Meanwhile, STX-1150 was projected to enter clinical trials in mid-2026, which would represent Scribe's first human proof-of-concept for the X-Editing platform. These milestones arrive against a backdrop of a competitive lipid-editing landscape that now includes Intellia, Verve, and others — timing and clinical differentiation will matter.
Key Personnel
Benjamin L. Oakes serves as Co-founder, President and CEO, and is among the core scientists who developed CRISPR-CasX at UC Berkeley before founding the company. Svetlana Lucas, PhD, serves as Chief Business Officer, leading the partnership strategy that has assembled more than $2.7 billion in total deal value. David Parrot, MBA, serves as Chief Financial Officer, overseeing capital allocation across the company's owned pipeline and partnered programs.
Strategic Partnerships
On May 16, 2023, Eli Lilly subsidiary Prevail Therapeutics launched an in vivo CRISPR collaboration with Scribe worth up to $1.5 billion, with $75 million in upfront and equity payments to Scribe, targeting neurological and neuromuscular disorders. Scribe also has a collaboration with Sanofi covering in vivo CRISPR applications, initially focused on sickle cell disease and other genomic diseases, under which Scribe received $40 million upfront and is eligible for up to $1.2 billion in milestones. Together these two deals provide Scribe with substantial non-dilutive runway and third-party validation of the X-Editing platform's versatility beyond cardiometabolic disease.
FAQ Section
Scribe is targeting PCSK9, LPA, and APOC3 because all three are genetically validated at population scale — human loss-of-function carriers show dramatically reduced cardiovascular risk with no apparent harm, which de-risks the biology considerably. The commercial logic is equally compelling: replacing a lifetime of daily statins or monthly injections with a single durable intervention addresses a massive chronic disease burden rather than an ultra-rare orphan condition. This is a deliberate pivot from the rare-disease playbook that defined early CRISPR programs and reflects confidence in the platform's ability to work efficiently in the liver.
CasX is a smaller enzyme than Cas9 and is not derived from pathogen molecules, which matters for two reasons: the smaller size enables more efficient packaging into delivery vehicles like lipid nanoparticles or AAV, and the non-pathogen origin may reduce the pre-existing immune responses that could limit re-dosing or efficacy of Cas9-based therapies. Scribe further engineers its CasX molecules through a directed design process — CRISPR by Design — optimizing the enzyme's properties rather than using sequences found in nature. The resulting X-Editing molecules are the company's core proprietary asset, distinct from what CRISPR Therapeutics, Intellia, or Verve are deploying.
Approved PCSK9 inhibitors — monoclonal antibodies and the RNA interference therapy inclisiran — require repeated dosing, either every two weeks, monthly, or twice yearly. STX-1150 is designed to silence the PCSK9 gene epigenetically through a single administration, aiming for durable LDL-C reduction without continuous therapy. The clinical and commercial case depends on that durability holding in humans; the biology is well validated, but the X-Editing platform has not yet generated human proof-of-concept data.
STX-1150 was projected to enter Phase I clinical trials in mid-2026, which would make it Scribe's first asset in human testing and the platform's first in vivo proof-of-concept. First-in-human data will need to demonstrate an acceptable safety profile — particularly absence of meaningful off-target editing events — and a pharmacodynamic signal: measurable, sustained reduction in LDL-C. Given the competitive landscape that includes Intellia's PCSK9 program and Verve's base-editing approach, the depth and durability of LDL-C lowering, not just safety, will define how investors read the readout.
Scribe's owned pipeline is tightly focused on cardiovascular and metabolic disease — LDL cholesterol via PCSK9 (STX-1150), lipoprotein(a) via LPA (STX-1200), and triglycerides via APOC3 (STX-1400). Through its Prevail partnership, the X-Editing platform also extends into neurological and neuromuscular disorders, and the Sanofi collaboration covers sickle cell disease and other genomic diseases. The breadth of partnered indications suggests the platform is liver-agnostic in principle, though Scribe's internal capital is concentrated on cardiometabolic targets where clinical precedent and genetic validation are strongest.
Scribe describes itself as clinical-stage, with STX-1150 projected to move into Phase I in mid-2026. STX-1200 and STX-1400 are both preclinical, with the CIRM funding announced in June 2026 intended to accelerate IND-enabling studies for both. The company's next twelve months are consequently milestone-dense: IND filing and first patient dosing for STX-1150, progress toward IND readiness for the CIRM-backed programs, and potential updates from the Prevail and Sanofi collaboration pipelines.
Key watchpoints over the next twelve to eighteen months include:
Latest Scribe Therapeutics News
Today's issue
| Headless Content Management with Blaze